SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2016
Commission File Number: 001-37710
HUTCHISON CHINA MEDITECH LIMITED
(Translation of registrant’s name into English)
22/F, Hutchison House, 10 Harcourt Road, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
HUTCHISON CHINA MEDITECH LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
|
Description |
|
|
|
Exhibit 99.1 |
|
Announcement relating to director’s share dealing |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
HUTCHISON CHINA MEDITECH LIMITED |
|
|
|
|
|
|
|
|
By: |
/s/ Johnny Cheng |
|
Name: |
Johnny Cheng |
|
Title: |
Chief Financial Officer |
Date: December 14, 2016
3
Exhibit 99.1
Director’s Share Dealing
London: Wednesday, December 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Simon To, Executive Director and Chairman, purchased a total of 52,161 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med ("Ordinary Share")) at an average price of US$14.18 per ADS on December 9, 2016, December 12, 2016 and December 13, 2016.
Following the above purchase of 52,161 ADSs, Mr To is interested in 52,161 ADSs and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in a family trust of which his family members are the beneficiaries), representing approximately 0.34% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
|
|
|
a) |
Name |
Mr Simon To |
|
2 |
Reason for the notification |
||
|
|
|
|
a) |
Position/status |
Executive Director and Chairman |
|
|
|
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
|
|
|
a) |
Name |
Hutchison China MediTech Limited |
|
|
|
|
|
b) |
LEI |
N/A |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument |
ADS each representing one half of one Ordinary Share of US$1.00
|
|
Identification code |
ADS ISIN: US44842L1035 |
||
|
|
|
|
b) |
Nature of the transaction |
Acquisition of ADSs |
|
|
|
|
|
|
|
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
US$14.05 |
10,000 |
|
|||
|
|
|
|
d) |
Aggregated information |
N/A |
|
|
— Aggregated volume |
|
|
|
— Price |
|
|
|
|
|
|
e) |
Date of the transaction |
2016-12-09 |
|
|
|
|
|
|
|
|
|
f) |
Place of the transaction |
Nasdaq Stock Market
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument |
ADS each representing one half of one Ordinary Share of US$1.00
|
|
Identification code |
ADS ISIN: US44842L1035 |
||
|
|
|
|
b) |
Nature of the transaction |
Acquisition of ADSs |
|
|
|
|
|
|
|
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
US$14.12 |
30,000 |
|
|||
|
|
|
|
d) |
Aggregated information |
N/A |
|
|
— Aggregated volume |
|
|
|
— Price |
|
|
|
|
|
|
e) |
Date of the transaction |
2016-12-12 |
|
|
|
|
|
|
|
|
|
f) |
Place of the transaction |
Nasdaq Stock Market
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument |
ADS each representing one half of one Ordinary Share of US$1.00
|
|
Identification code |
ADS ISIN: US44842L1035 |
||
|
|
|
|
b) |
Nature of the transaction |
Acquisition of ADSs |
|
|
|
|
|
|
|
|
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
US$14.43 |
12,161 |
|
|||
|
|
|
|
d) |
Aggregated information |
N/A |
|
|
— Aggregated volume |
|
|
|
— Price |
|
|
|
|
|
|
e) |
Date of the transaction |
2016-12-13 |
|
|
|
|
|
|
|
|
|
f) |
Place of the transaction |
Nasdaq Stock Market
|
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries Christian Hogg, CEO |
+852 2121 8200 |
|
|
|
|
International Media Enquiries |
|
|
Anthony Carlisle, Citigate Dewe Rogerson |
+44 7973 611 888 (Mobile) |
anthony.carlisle@cdrconsultancy.co.uk |
|
|
|
U.S. Based Media Enquiries |
|
|
Brad Miles, BMC Communications |
+1 (917) 570 7340 (Mobile) |
bmiles@bmccommunications.com |
Susan Duffy, BMC Communications |
+1 (917) 499 8887 (Mobile) |
sduffy@bmccommunications.com |
|
|
|
Investor Relations |
|
|
Matt Beck, The Trout Group |
+1 (917) 415 1750 (Mobile) |
mbeck@troutgroup.com |
David Dible, Citigate Dewe Rogerson |
+44 7967 566 919 (Mobile) |
david.dible@citigatedr.co.uk |
|
|
|
Panmure Gordon (UK) Limited |
|
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
|